VERTEX PHARMACEUTICALS INC / MA·4

May 5, 5:37 PM ET

Thornberry Nancy 4

4 · VERTEX PHARMACEUTICALS INC / MA · Filed May 5, 2026

Research Summary

AI-generated summary of this filing

Updated

Vertex (VRTX) Director Nancy Thornberry Receives RSU Award, Defers 398 Shares

What Happened Nancy Thornberry, a director of Vertex Pharmaceuticals (VRTX), received equity awards on May 1, 2026. The filing shows 1,433 shares acquired on vesting of RSUs (derivative, fully vested), a new grant of 472 restricted stock units (RSUs) that vest on the first anniversary of the grant, and a disposition of 398 shares to the issuer in exchange for 398 deferred stock units under Vertex’s deferred compensation plan. All awards show a $0.00 per-share acquisition price (typical for RSUs).

Key Details

  • Transaction date: 2026-05-01; Form 4 filed 2026-05-05 (timely).
  • Grants/acquisitions:
    • 1,433 shares (derivative) acquired on vesting; footnote indicates fully vested (F3).
    • 472 RSUs granted that vest on the first anniversary of the grant (F1).
  • Disposition/deferment:
    • 398 shares reported as disposed to the issuer in exchange for 398 deferred stock units (F2). Those deferred stock units each represent one share and will be paid in stock on certain events (termination, change of control, disability or death) (F4).
  • Prices/values: all acquisitions reported at $0.00 per share (no cash paid); the disposition was an in-kind exchange (not a market sale).
  • Shares owned after the transaction: not specified in the provided filing excerpt.

Context

  • These transactions consist of RSU vesting, a new RSU grant, and a deferral into deferred stock units — not open-market buying or selling. RSU grants and deferrals are common compensation actions and do not by themselves indicate a buying or selling decision in the market.
  • Deferred stock units are treated as a form of delayed compensation and convert to common shares only upon the specified payout events.

Insider Transaction Report

Form 4
Period: 2026-05-01
Transactions
  • Award

    Common Stock

    [F1]
    2026-05-01+4722,507 total
  • Disposition to Issuer

    Common Stock

    [F2]
    2026-05-013982,109 total
  • Award

    Stock Option (Right to Buy)

    [F3]
    2026-05-01+1,4331,433 total
    Exercise: $424.45Exp: 2036-04-30Common Stock (1,433 underlying)
  • Award

    Deferred Stock Units

    [F4][F2]
    2026-05-01+398398 total
    Common Stock (398 underlying)
Footnotes (4)
  • [F1]Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date.
  • [F2]Upon the vesting of restricted stock units granted to Ms. Thornberry on May 1, 2025, Ms. Thornberry deferred the receipt of 398 shares of common stock and received instead 398 deferred stock units pursuant to our deferred compensation plan. As a result, Ms. Thornberry is reporting the disposition of 398 shares of common stock in exchange for an equal number of deferred stock units.
  • [F3]Fully vested.
  • [F4]Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. Thornberry's service on our board of directors, (ii) a change of control of our company and (iii) Ms. Thornberry's disability or death.
Signature
/s/ Christiana Stevenson, Attorney-in-Fact|2026-05-05

Documents

1 file
  • 4
    wk-form4_1778017046.xmlPrimary

    FORM 4